跳至主要内容
欧盟官方标签名称词汇表条目 2245

ARGININE HCl

本记录确认了用于欧盟化妆品标签标示的官方通用成分名称。它本身并不能确认该物质获准使用、不受限制或安全。

全球证据概览

所解析的身份在 13 个已索引市场数据集中的 0 个有匹配的监管证据:0 条国家记录和 0 条欧盟附件记录。下方列出每项结果和证据缺口。

0 个市场有证据
已检查的市场
13
有证据的市场
0
证据缺口
13
已解析的标识符
2

已解析的物质身份

CAS:1119-34-2
EC:214-275-1
成分索引记录:
ARGININE HCL
化妆品功能: SKIN CONDITIONING

L-Arginine hydrochloride

1 个匹配或报告的名称
ARGININE HCL

跨市场监管证据

此处跟踪的 13 个市场均没有以 ARGININE HCl 为名的已导入规则。

这是关于本清单的陈述,而非关于法律的陈述:没有已导入的规则并不能证明某物质获准使用。规则可能以其他名称存在,或以本词汇表条目未载有的 CAS 或 EC 编号存在,或存在于尚未导入的数据集中。

化学身份与性质

CAS 1119-34-2 的 PubChem 二维化学结构
CAS 1119-34-2PubChem CID 66250

L-Arginine, monohydrochloride

Arginine hydrochloride is a L-alpha-amino acid. — ChEBI

IUPAC 名称
(2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;hydrochloride
分子式
C6H15ClN4O2
分子量
210.66 g/mol
精确质量
210.0883534 Da
拓扑极性表面积
128.0 Ų
氢键供体
5
氢键受体
4
共价单元
2
已定义的立体中心
1

又称

Arginine HydrochlorideL-ARGININE HCLR-GeneR-gene 10F7LTH1E20YNSC-203450NSC-7914Hydrochloride, arginine
另有 16 个已报告名称
NSC7914RefChem:5562214-275-1L-Arginine hydrochlorideL-Arginine monohydrochlorideH-Arg-OH.HClArginine HClArginine monohydrochlorideArgamineArgiveneDetoxarginL-(+)-Arginine monohydrochlorideLevarginL-Arginine, hydrochloride (1:1)Minophagen A(+)-L-Arginine hydrochloride
外部数据库标识符

来自其他科学数据库的证据

NIH PubChem PUG-View
标识符精确匹配66250

Attributed physical-property, hazard, environmental and use annotations.

  • Exposure Routes: Absorbed from the lumen of the small intestine into the enterocytes. Absorption is efficient and occurs by an active transport mechanism. 来源: Toxin and Toxin Target Database (T3DB)
  • Note: This chemical does not meet GHS hazard criteria for 67.8% (269 of 397) of all reports. 来源: European Chemicals Agency (ECHA)
  • Signal: Warning 来源: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H315 (31.7%): Causes skin irritation [Warning Skin corrosion/irritation]; H319 (32.2%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] 来源: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P264, P264+P265, P280, P302+P352, P305+P351+P338, P321, P332+P317, P337+P317, and P362+P364 (click each P-code to see the statement) 来源: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 397 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 269 of 397 reports by companies.; There are 3 notifications provided by 128 of 397 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. 来源: European Chemicals Agency (ECHA)
  • Cosmetic Ingredient Review Finding(s): Safe in the present practices of use and concentration. Ingredient, concentration, and use information are available in documents discoverable at https://cir-reports.cir-safety.org 来源: Cosmetic Ingredient Review (CIR)
  • Toxicity Summary: Many of supplemental L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3,'5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase. NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues su 来源: Toxin and Toxin Target Database (T3DB)

映射方: Existing checksum-valid CAS to unique PubChem CID match. 检索时间: 2026-08-31. 打开来源记录

科学分类和危害注释仅提供背景信息,不能取代上方所示针对具体市场的监管决定。

其他来源的覆盖范围和匹配状态
来源结果已检查
NIH PubChem PUG-View精确匹配2026-08-31

已记录的无匹配结果是该来源已被检查的有效证据;这并不表示该物质在别处不存在。

于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

进一步查看此记录

在配方中筛查打开独立对比

官方来源与范围

导入自委员会实施决定 (EU) 2025/1175(数据集版本 EU 2025/1175)。词汇表为第 19(1)(g) 条所要求的成分表提供通用成分名称;它不是准许清单或安全清单。

打开官方决定